Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Lymphoplasmacytoid Lymphoma: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Lymphoplasmacytoid Lymphoma: 1 US clinical trial tracked, none currently recruiting.

Lymphoplasmacytoid Lymphoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), running 1 of these trials.

Enrollment posture brief

Registry condition lymphoplasmacytoid-lymphoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Lymphoplasmacytoid Lymph (th…0%
Open-enrollment share among volume-matched conditions near Lymphoplasmacytoid Lymphoma

Lymphoplasmacytoid Lymphoma has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lymphoplasmacytoid Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lymphoplasmacytoid Lymphoma is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Lymphoplasmacytoid Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Zilovertamab vedotin Drug
1 trials

US sites by state

Facility locations filed on Lymphoplasmacytoid Lymphoma trials. A trial with sites in several states counts in each.

Washington 1 trials
Virginia 1 trials
Texas 1 trials
Oregon 1 trials
New York 1 trials
Nebraska 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lymphoplasmacytoid Lymphoma page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoplasmacytoid Lymphoma condition card totals 1 registered trials; most-linked intervention Zilovertamab vedotin; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.